title: Cadazolid for the treatment of Clostridium difficile.
abstract: Antibiotic development goals for CDI include potent antimicrobial effect against C. difficile, limited killing of host microbiota, potential effect on spores, and ability to interfere with toxin production. Cadazolid, a novel, non-absorbable hybrid antibiotic has many of these criteria. In phase I and II clinical trials, cadazolid was shown to be safe, well tolerated, and efficacious positioning itself as a potential future viable therapeutic option for CDI. Areas covered: This review provides an in-depth evaluation of the chemistry, microbiology, pharmacodynamics, pharmacokinetics, and clinical trial results for cadazolid. Clinical therapeutic outcomes are compared between cadazolid, fidaxomicin, and surotomycin. Expert opinion: Preclinical and early clinical studies demonstrated that cadazolid has unique properties that will likely be valuable to treat CDI and reduce recurrent infection. With compelling phase II clinical results, results from the ongoing phase III trial will better define the role of cadazolid for treating CDI in the future.
authors.affiliation: a Department of Pharmacy Practice and Translational Research , University of Houston College of Pharmacy , Houston , TX , USA.
authors.forename: Bradley T
authors.initials: BT
authors.lastname: Endres
authors.affiliation: a Department of Pharmacy Practice and Translational Research , University of Houston College of Pharmacy , Houston , TX , USA.
authors.forename: Eugénie
authors.initials: E
authors.lastname: Bassères
authors.affiliation: a Department of Pharmacy Practice and Translational Research , University of Houston College of Pharmacy , Houston , TX , USA.
authors.forename: M Jahangir
authors.initials: MJ
authors.lastname: Alam
authors.affiliation: a Department of Pharmacy Practice and Translational Research , University of Houston College of Pharmacy , Houston , TX , USA.
authors.forename: Kevin W
authors.initials: KW
authors.lastname: Garey
mesh_terms: D000617:Aminoglycosides / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D016360:Clostridioides difficile / Q000187:drug effects*; D003015:Clostridium Infections / Q000188:drug therapy* / Q000382:microbiology; D000077732:Fidaxomicin; D006801:Humans; D055666:Lipopeptides / Q000627:therapeutic use; D023303:Oxazolidinones / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D010456:Peptides, Cyclic / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; C574454:CB-183,315; D055666:Lipopeptides; D023303:Oxazolidinones; D010456:Peptides, Cyclic; C000591679:cadazolid; D000077732:Fidaxomicin
keywords: Antibiotic; Clostridium difficile; anaerobic infections; cadazolid; diarrhea; vancomycin